GlaxoSmithKline (GSK) is rising this morning, after the company announced that its experimental HIV treatment dolutegravir reduced the level of the virus in the blood of patients who had taken it in conjunction with two other drugs. The company claimed that the treatment actually reduced the virus more than Gilead’s (GILD) Atripla, which is the [...]